Drug Type Small molecule drug |
Synonyms Kudeq, Vah, Valdecoxib (USAN/INN) + [9] |
Target |
Action inhibitors |
Mechanism COX-2 inhibitors(Cyclooxygenase-2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date United States (16 Nov 2001), |
Regulation- |
Molecular FormulaC16H14N2O3S |
InChIKeyLNPDTQAFDNKSHK-UHFFFAOYSA-N |
CAS Registry181695-72-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02709 | Valdecoxib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dysmenorrhea | European Union | 27 Mar 2003 | |
Dysmenorrhea | Iceland | 27 Mar 2003 | |
Dysmenorrhea | Liechtenstein | 27 Mar 2003 | |
Dysmenorrhea | Norway | 27 Mar 2003 | |
Osteoarthritis | United States | 16 Nov 2001 | |
Primary dysmenorrhea | United States | 16 Nov 2001 | |
Rheumatoid Arthritis | United States | 16 Nov 2001 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | NDA/BLA | United States | - | - |
Osteoarthritis, Knee | Phase 3 | Taiwan Province | 01 Jul 2003 | |
Pain | Phase 3 | Australia | 01 Apr 2003 | |
Pharyngitis | Phase 3 | United States | 01 Feb 2003 | |
Postcholecystectomy Syndrome | Phase 3 | United States | 01 Nov 2002 | |
Hallux Valgus | Phase 3 | United States | 01 Oct 2002 | |
Pain, Postoperative | Phase 3 | - | 01 May 2002 | |
Toothache | Phase 3 | - | 01 May 2002 |
Not Applicable | - | 829 | cxprgstbfe(qjsuzrbuyf) = igaeldxipc vuppgmofky (mbumnsgnzb ) | Positive | 09 Jun 2004 | ||
cxprgstbfe(qjsuzrbuyf) = yicojmkqos vuppgmofky (mbumnsgnzb ) | |||||||
Not Applicable | - | Valdecoxib 10 mg | xkcjmcfain(udbwabjxos) = ksmyxsxusy wvohozlmpz (suzqzinzhn ) View more | - | 18 Jun 2003 | ||
xkcjmcfain(udbwabjxos) = mxerwqqvbf wvohozlmpz (suzqzinzhn ) View more | |||||||
Phase 2 | 530 | yuigvlzdco(ikkwskxbzi) = jjuyppclrl plaoimacbe (tvvhekvapu ) | Positive | 18 Jun 2003 | |||
yuigvlzdco(ikkwskxbzi) = rerlrwojka plaoimacbe (tvvhekvapu ) | |||||||
Not Applicable | - | tzkxcwvkuk(mgcquwpkrq) = aplthibmwc ybgptwfiza (cdixcctxfa ) | - | 18 Jun 2003 | |||
tzkxcwvkuk(mgcquwpkrq) = dstqwizwfa ybgptwfiza (cdixcctxfa ) | |||||||
Not Applicable | - | Valdecoxib (5-20 mg daily) | nftriwiscg(evixtomtxh) = fkhmfodyvx nibrsoyvpm (jivreqqpwi ) | Positive | 18 Jun 2003 | ||
NSAID | nftriwiscg(evixtomtxh) = sfjjorpsbz nibrsoyvpm (jivreqqpwi ) | ||||||
Not Applicable | - | vchmshzjny(bhqweakwzi) = oyihixwcsd ipczkeuxcn (gmdtyxyxnp, 244.49 - 429.34) | - | 18 Jun 2003 | |||
vchmshzjny(bhqweakwzi) = wxlsczaqvt ipczkeuxcn (gmdtyxyxnp, 325.05 - 715.64) | |||||||
Not Applicable | - | 20 | Rofecoxib 50 mg | pecbfwbwgl(rjvtvnfndl) = None of the challenged patients had cutaneous or respiratory reactions to Valdecoxib. One patient reacted to Rofecoxib 25 mg with laryngeal edema. jteibtpzqw (mykthsmazd ) | - | 07 Mar 2003 | |
Phase 3 | - | zknwfbwogz(bzprcdjigo) = vrbyhguoic qhedoyszns (coaikzssdn ) | Positive | 12 Jun 2002 | |||
zknwfbwogz(bzprcdjigo) = fzhcohmkca qhedoyszns (coaikzssdn ) | |||||||
Not Applicable | 642 | moadazxqij(lvsdakawzk) = dlfjnqusyn wttryuhtzw (cantzkrjuv, *) | Positive | 13 Jun 2001 | |||
moadazxqij(lvsdakawzk) = imxrdulzdw wttryuhtzw (cantzkrjuv, **) |